Additional file 1: of Sexual, ontogenetic, and geographic variation of the Neotropical freshwater ostracod Cytheridella ilosvayi

Table S1. Overview of soft part ratios of Cytheridella with additional information about number of eggs and larvae found in female brood pouches and juveniles with anlagen of reproductive organs. Asterisks refer to specimens obtained from [31]. (XLSX 70 kb

Additional file 4: of Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

Body weight variation in A549 xenograft antitumoral efficacy assay. Animal body weight was monitored weekly after intratumoral injection of PBS, ICO15K or ICO15K-FBiTE (2 × 109 vp). Mean values ± SEM are plotted (n = 6–7). (DOCX 140 kb

Additional file 3: of Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

Characterization of GFP- and CBG Luciferase-expressing T cells. A. Flow cytometry analysis of GFP expression of preactivated T-cells that had been transduced with a lentiviral vector encoding GFP and the click beetle green (CBG) luciferase. B. Percentages of CD4 and CD8 LUC-T-cells populations determined by flow cytometry. (DOCX 231 kb

Additional file 5: of Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

Antitumor activity of ICO15K-FBiTE. NSG mice bearing subcutaneous xenografts of A549 or HPAC tumors were injected intratumorally with PBS or 2 × 109 viral particles of ICO15K or ICO15K-FBiTE. The mean tumor volume ± SEM of ≥12 tumors per group is shown. *, significant (P < 0.05) by one-way ANOVA test with post hoc analysis compared to ICO15K group. #, significant (P < 0.05) by one-way ANOVA test with post hoc analysis compared to PBS group. (DOCX 195 kb

Additional file 1: of Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

FBiTEs molecules expressed from ICO15K-FBiTE-infected cells induce T-cells proliferation when co-cultured with PBMCs. 293, 293mFAP and 293hFAP were co-cultured with CFSE-labeled PBMCs and indicated supernatants. Six days after co-culture, the CFSE content in CD4+ and CD8+ T-cells was determined by flow cytometry. A representative result of triplicates is shown. (DOCX 13487 kb

Additional file 2: of Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager

FBiTE-mediated bystander tumor cell killing. A, B. CFSE-stained HT cells (A) or A431 cells (B) were culture in the presence of T cells and its derivative mFAP- or hFAP cells and the indicated supernatants (mock, ICO15K or ICO15K-FBiTE) were added. After 24 h, cytotoxicity of HT cells (A) or A431 cells (B) and its mFAP- or hFAP-derivative cells were evaluated by flow cytometry. Mean values ± SD are plotted in A, B (n = 3). ***, significant (P < 0.001) by one-way ANOVA test with post hoc analysis compared to mock and ICO15K. **, significant (P < 0.01) by one-way ANOVA test with post hoc analysis compared to mock and ICO15K. (DOCX 168 kb

Photoluminescence Enhancement by Band Alignment Engineering in MoS₂/FePS₃ van der Waals Heterostructures

Single-layer semiconducting transition metal dichalcogenides (2H-TMDs) display robust excitonic photoluminescence emission, which can be improved by controlled changes to the environment and the chemical potential of the material. However, a drastic emission quench has been generally observed when TMDs are stacked in van der Waals heterostructures, which often favor the nonradiative recombination of photocarriers. Herein, we achieve an enhancement of the photoluminescence of single-layer MoS2 on top of van der Waals FePS3. The optimal energy band alignment of this heterostructure preserves light emission of MoS2 against nonradiative interlayer recombination processes and favors the charge transfer from MoS2, an n-type semiconductor, to FePS3, a p-type narrow-gap semiconductor. The strong depletion of carriers in the MoS2 layer is evidenced by a dramatic increase in the spectral weight of neutral excitons, which is strongly modulated by the thickness of the FePS3 underneath, leading to the increase of photoluminescence intensity. The present results demonstrate the potential for the rational design of van der Waals heterostructures with advanced optoelectronic properties

MOESM1 of Peroxisome Proliferator-Activated Receptor γ 2 Modulates Late-Pregnancy Homeostatic Metabolic Adaptations

Peroxisome Proliferator-Activated Receptor γ 2 Modulates Late-Pregnancy Homeostatic Metabolic Adaptation

Additional file 1 of Acute expression of human APOBEC3B in mice results in RNA editing and lethality

Additional file 1. Supplementary figures

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div